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Abstract, Experimental data derived from animal 
models suggest that the endogenous nucleoside adeno­
sine has important cardioprotective properties. The 
potent vasodilator effects of adenosine may contribute 
to this cardioprotection as ischaemia-induced release 
of endogenous adenosine has been suggested to adjust 
local blood flow to the metabolic demands of the 
tissue. Interestingly, the vascular effects of adenosine 
appeared to be impaired in animal models for diabetes 
mellitus. This observation may be of importance with 
respect to the increased cardiovascular mortality 
in diabetes. Therefore, the authors investigated the 
in vivo vasodilator effects of adenosine in insulin- 
dependent diabetic patients. In 12 uncomplicated 
insulin-dependent male diabetic patients and 12 
healthy male age-matched subjects, the brachial 
artery was cannulated for infusion of adenosine
(0T5, 0-5, 1-5, 5, 15 and 50yUg 100~l mLmin” 1) and 
for measurement of mean arterial pressure (MAP). 
Forearm blood flow (FBF) was measured by venous 
occlusion mercury-in-silastic strain gauge plethysmo­
graphy. Maximal vasodilatation was assessed by stan­
dardized post occlusive reactive hyperaemia (PORH). 
Baseline forearm blood flow was 2*7 ±0*4 and 
1-8 ± 0*2 mL 1(XH mLmin“ 1 for the diabetic patients 
and control group respectively. In the diabetic 
patients, adenosine infusion raised forearm blood 
flow to 2*4 ±0-4, 2*6 ±0*4, 4*4 ±  0*7, 6*3 ±  1*0, 
9*8 ±1*5 and 14*2± 2-1 mLlOO-1 mLmin-1 for the 
respective dosages. In the control group these 
values were 1*7±0’2, 1-9 ±0-3, 3*2 ±0*8, 6*0 ±1*2, 
10*9 ± 2*1 and 17*1 ±3*4 mL 100” 1 mLmin-1 respec­
tively (P > 0*1 for between group comparison). Fore­
arm blood flow at the contralateral side was not 
significantly affected by the placebo and adenosine 
infusions. Similar results were obtained when results 
were expressed as changes in forearm vascular resist­
ance or forearm blood flow ratio (FBF infused arm/ 
FBF control arm). Maximal vasodilatation did not 
differ between the two groups. The authors conclude
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that the forearm vasodilator response to adenosine 
is preserved in uncomplicated insulin-dependent 
diabetic patients. This observation argues against a 
primary role of a reduced adenosine responsiveness in 
the cardiovascular sequelae of diabetes.
»
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Introduction
Adenosine has potentially important cardioprotective 
properties such as inhibition of neutrophil activation 
with subsequent reduced free radical formation, 
inhibition of thrombocyte aggregation, vasodila­
tation, presynaptic inhibition of noradrenaline release 
and opening of potassium channels [1]. These effects 
are mediated by adenosine receptors, located on 
the outer cell membrane. In animals, myocardial 
infarct size is reduced when adenosine is infused 
either before ischaemia or during the reperfusion 
period [2-4]. In addition, adenosine reduces the 
incidence of ischaemia-induced arrhythmias [5]. 
Infusion of a selective adenosine receptor antagonist 
increases infarct size, indicating a role for endogenous 
adenosine as a cardioprotective autacoid [6], As the 
vasodilator action of adenosine is thought to play a 
role in the local adjustment of oxygen demand to 
oxygen supply [7,8], this may contribute to the cardio­
protective properties of adenosine.
Interestingly, an impaired responsiveness to the 
vasodilator effect of adenosine has been observed in 
animal models of diabetes mellitus [9,10]. Several 
mechanisms may be responsible for this reduced 
responsiveness to adenosine, Animal and human 
data have indicated both facilitating as well as inhibit­
ing interactions between adenosine and the sympa­
thetic nervous system [11-16]. Furthermore, human 
and animal studies show that adenosine-induced 
vasodilatation is at least partially mediated by the 
endothelium [17-19]. As insulin alters sympathetic 
nervous system activity [20 ,21] and diabetes mellitus 
has been associated with reduced endothelium-depen­
dent vasodilatation [22-25], both neural and endo­
thelial mechanisms may be involved in the reduced
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reactivity to adenosine in these descriptive animal 
studies. Additionally, direct actions of adenosine on 
cardiac and vascular muscle cells may be reduced in 
patients with diabetes mellitus.
Although vascular reactivity in human diabetes 
has been studied extensively over the past few years 
[22-25], no human data are available on responsive­
ness to the endogenous nucleoside adenosine. As 
diabetes is an independent risk factor for developing 
cardiovascular disease [26], and is often associated 
with concomitant hypercholesterolaemia and hyper­
tension, which further contributes to an increased risk 
of ischaemic heart disease [27,28], an impairment in 
adenosine responsiveness may be of clinical interest. 
Pharmacological compounds are currently being 
developed to potentiate the action of endogenous 
adenosine at sites of ischaemia [12]. In this context it 
is valuable to know whether diabetic patients exhibit 
decreased responses to adenosine. Furthermore, a 
reduced vascular responsiveness to adenosine may 
also be of importance in the metabolic control of 
patients with diabetes mellitus as adenosine enhances 
glucose uptake in some animal models [29,30]. This 
metabolic effect of adenosine may in part be a result of 
its effect on blood flow [31]. Therefore, we evaluated 
the vasodilator response to adenosine in patients with 
uncomplicated insulin-dependent diabetes mellitus 
and compared these observations with a carefully 
matched control group.
Patients and methods
Patients
After approval of the local ethics committee, 12 
normotensive non-smoking Caucasian male patients 
with insulin-dependent diabetes mellitus were selected 
from our outpatient population. Diabetes mellitus 
was diagnosed at least 5 years before participation 
in this study. Patients with evidence of macro- or 
microvascular disease were excluded from the study
because these vascular complications would result in a 
non-specific impairment of reactivity to any vaso­
dilator substance. Macro vascular disease was assessed 
by taking patients’ history (no coronary artery dis­
ease, heart failure, cerebrovascular disease, peripheral 
vascular disease or foot ulcers), physical examination 
and a 12-lead electrocardiogram. Microvascular dis­
ease was excluded by demonstrating the absence of 
orthostatic hypotension and peripheral loss of sensi­
bility, by a normal fundoscopy and by an albumin 
excretion ratio less than 20/igmin-1. None of the 
patients used medication other than subcutaneous 
insulin injection. Only patients with a glycosylated 
haemoglobin concentration (HbAlc) between 7% 
and 10% as measured during insulin treatment were 
included. The control group consisted of 12 male non­
smoking healthy Caucasian volunteers. These subjects 
were carefully matched for age, blood pressure and 
body weight. They had no history of diabetes mellitus 
and did not use concomitant medication. Physical 
examination and 12-lead electrocardiography did 
not reveal any abnormalities. Demographic data of 
the study groups are shown in Table 1.
Methods
Before the start of the study, the subjects were asked 
to abstain from caffeine-containing products for at 
least 24 h, because caffeine is a potent adenosine 
receptor antagonist [32]. In all participating subjects, 
the plasma caffeine concentration was below the limit 
of detection as measured in a sample that was 
collected immediately before starting the experiments 
[reversed-phase high-performance liquid chroma­
tography (HPLC); minimal level of detection: 
0*2^gm l" 1 [33]]. All tests were performed in a 
temperature-controlled laboratory (22-23°C), with 
participants in the supine position, after an overnight 
fast, starting at 8.00 a.m.
From a methodological point of view, the level of 
plasma insulin and glucose concentrations throughout
Table 1. Demographie characteristics of the study groups (mean ±  SD)
Diabetic subjects Healthy subjects
n 12 12
Male/female 12/0 12/0
Age (years) 34-6 ±  5-9 34*8 ±  6-0
Body mass index (kgm~2) 23-6 ±  2-4 23 3 ±  2-4
Systolic blood pressure (mmHg)* 123 ±  10*4 118 ±  8-2
Diastolic blood pressure (mmHg)* 63*2 ±  8-6 62-4 ±  4-9
Mean arterial pressure (mmHg)* 85-2 ±  9-8 82-4 ±  6*8
Heart rate (beats m h ir1)f 67-3 ±  16-8 57‘4 ±  9-6
HbAlc (%) 8-5 ±  0*9
Time after diagnosis (years) 16-2 ±  8*3
Glucose (mmol L~!)t 13-0 ±  5*Î
*Intra-arterially measured during placebo infusion, tMeasured by electrocardiographic 
recordings during placebo infusion, f Determined during the experiment; for each subject 
the six determinations were averaged to one value.
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the study is a very important issue. Recent studies 
have convincingly shown that baseline skeletal muscle 
flow in humans is not affected by hyperglycaemia [34], 
whereas hyperinsulinaemia induces an obvious 
increase in baseline skeletal muscle flow and affects 
forearm vascular reactivity [35-38]. To avoid con­
founding of our results by insulin-mediated vasodila­
tation, we instructed the diabetic subjects to skip their 
morning dose of insulin and not to have breakfast. 
This was done in order to achieve low and steady state 
plasma insulin levels during the experiments. 
Although even lower insulin levels would have been 
reached by also skipping the long-acting insulin injec­
tion of the evening before the experiment, this would 
have introduced the risk of the development of ketosis 
or ketoacidosis, a factor which would certainly have 
affected the results. As no insulin was administered in 
the morning hours, we had to accept the varying 
fasting glucose levels throughout the experiments, as 
correcting the glucose levels would inevitably have 
increased insulin levels. As stated above, recent data 
have convincingly shown that plasma glucose levels 
up to 15 mmol L affect neither baseline forearm blood 
flow nor vascular reactivity of the forearm vascular 
bed [34].
After local anaesthesia (xylocaine, 2%), the left 
brachial artery was cannulated with a 20-gauge 
catheter (Angiocath, Deseret Medical, Becton Dick­
inson, Sandy, UT, USA) for both intra-arterial ade­
nosine infusion (automatic syringe infusion 
pump, type STC-521, Terumo Corporation, Tokyo, 
Japan) and blood pressure recording (Hewlett 
Packard, Böblingen, Germany). Forearm blood 
flow was registered simultaneously on both forearms 
by electrocardiography-triggered venous occlusion 
plethysmography using mercury-in-silastic strain 
gauges (Hokanson EC4, D.E. Hokanson, Washing­
ton, USA). The upper arm collecting cuff was inflated 
using a rapid cuff inflator (Hokanson E-20, D.E. 
Hokanson). At least 1 min before the FBF measure­
ments, the circulation of the left hand was occluded by 
inflation of a wrist cuff to 200 mmHg. Forearm blood 
flow was recorded three times per minute during the 4- 
min placebo infusion and during the last 2 min of each 
adenosine infusion.
The experiment started with the measurement of 
baseline forearm blood flow during placebo infusion 
(NaCl, 0-9%). Apart from the course in the forearm 
blood flow, Fig.l shows the schedule of the several 
drug infusions. The effect of six increasing dosages of 
adenosine (Sigma, St Louis, MO, USA; 0-15, 0’5, 1-5,
5, 15 and 50/igl00mL forearm min-1) were com­
pared with placebo (NaCl 0-9%). Prolonged occlusion 
of the hand circulation can cause discomfort with 
subsequent effects on blood pressure and heart rate. 
Therefore, a 5-min rest period with desufflation of 
the wrist cuffs was allowed between the placebo 
infusion and the first adenosine dose and between 
the third and fourth adenosine doses. During all 
procedures, total volume infusion was adjusted to
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Figure T. The course in forearm blood flow (FBF) before and during 
the intra-arterial infusion of adenosine is presented for the diabetic 
patients and the control group. There was no statistically significant 
difference between the groups ( a n o v a  for repeated measurements: 
P =  1-0). Diabetic patients, control arm ( • ) ;  controls, control arm 
(O); diabetic patients, infused arm ( • ) ;  controls infused arm (O). □, 
Placebo to infusion (NaCl 0*9%); ■, incremental adenosine infusions.
forearm volume as measured by water displacement 
and kept at a constant rate of lOO/^LlOOmL 
forearm min-1. Placebo and each adenosine dosage 
were infused over 4 min.
To exclude structural vascular changes in 
the diabetic patients, maximal vasodilatation was 
measured during post occlusive reactive hyperaemia 
(PORH) according to the well-established method 
of Pedrinelli et al. [39,40] 20 min after the end of 
the final adenosine infusion. A cuff applied to the 
left upper arm was inflated to 300 mmHg for 
13 min. During the last minute of ischaemia the 
subjects were asked to perform repeated hand con­
tractions. Immediately after desufflation of the 
upperarm cuff, FBF measurements were started 
for at least 2 min with occluded hand circulation. 
The lowest forearm vascular resistance (MAP/FBF) 
was considered to represent maximal vasodilation.
In the diabetic group, blood glucose concentra­
tions were determined six times: immediately 
after arterial cannulation, after infusion of placebo, 
after the third and after the sixth adenosine dose, 
just before the test of maximal vasodilatation 
and just before decannulation (Accutrend, type 
1284851, Boehringer, Mannheim, Germany). Before 
the intra-arterial adenosine infusions, lOmL of 
arterial blood was collected with lithium-heparin as 
coagulant in nine diabetic patients and in four con­
trol subjects for the determination of plasma insulin 
and detection of insulin antibodies. Plasma insulin 
was measured by radioimmunoassay using a specific 
antiserum raised in a guinea pig against human 
insulin. A second antibody was used to separate the 
antibody-bound and free fractions. Insulin antibodies 
were detected by incubation of the samples with 
[125I]-insulin and subsequent precipitation with 
polyethyleneglycol [41].
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Statistics
Mean arterial pressure (MAP) was measured contin­
uously during each recording of forearm blood flow 
(FBF) and averaged per FBF registration. Forearm 
vascular resistance (FVR) was calculated from simul­
taneously measured MAP and FBF (MAP/FBF) and 
expressed as arbitrary units (AU). Additionally, the 
ratio of each simultaneously measured FBF (FBF 
infused arm/FBF control arm) was calculated. Fore­
arm blood flows, the calculated flow ratios and FVRs 
obtained during each 4 min of placebo infusion or 
during the last 2 min of each drug infusion were 
averaged to one value. Adenosine-induced effects 
were expressed both as absolute and percentage 
change from preceding placebo, infusion. Differences 
in responses to adenosine between the two study 
groups were analysed with an a n o v a  for repeated 
measurements with the adenosine dosage as within- 
subject factor and the presence of diabetes mellitus 
as between-subject factor. Differences in baseline 
values were assessed with the unpaired Student t- 
test. Correlations were performed using the Pearson 
correlation coefficient. Since plasma insulin concen­
trations did not show a Gaussian distribution, 
group differences in insulin levels were analysed 
by the M ann-W hitney [/-test. All results are 
expressed as mean ±  SE unless indicated otherwise; 
P< 0*05 (two-sided) was considered to indicate 
statistical significance.
Results
Baseline FBFs in the infused arm were 2*7 ±0*4 and 
1*8 ± 0 '2 m L  lOOmL“ 1 forearm min“ 1 for the diabetic
patients and control group, respectively (P =  0-07). 
In the control arm these values were 2*4 ±0*4 
and l -5 ± 0 ‘lm L100m l~1 forearmmin" 1 (P — 0-05). 
During the adenosine infusions, FBF in the infused 
arm of the diabetic patients amounted to 2-4 ± 0 *4 , 
2*6±0*4, 4*4±0-7, 6*3±1*0, 9*8±1*5 and 14-2±  
2T mL lOOmL-1 forearm min" 1 for the respective 
adenosine dosages of 0-15, 0*5, 1*5, 5, 15 and 50 ^g 
adenosine lOOmL-1 forearmmin-1. In the control 
group these values were 1*7 ± 0-2 , 1-9 ± 0 -3,
3*2±0*8, 6-0±  1-2 , 10*9±2-1 and 17-l±3-4m L
lOOmL“ 1 forearmmin“ 1, respectively (see Fig.l). In 
both groups, FBF in the control arm was not sig­
nificantly affected during the placebo and adenosine 
infusions. Overall, repeated measures ANOVA did 
not reveal a significant difference between the two 
groups (between subject effect: P = l - 0 ) .  Similar 
results were obtained when results were expressed as 
absolute or relative changes in FBF from baseline.
Baseline FVRs in the infused arm were 39*6 ±5*2 
and 57*5 ±  7*6 AU for the diabetic patients and con­
trols, respectively (P =  0*07). In the control arm these 
values were 45*7 ±  6*3 and 63*7 dh 5*9 AU, respectively 
(P < 0-05). During adenosine infusion, FVRs in the 
infused arm of the diabetic patients were 44*6 ± 6*6, 
41*9 ±5*4, 29*9 ±7*1, 20*5 ±4*6, 16*6 ±5*7 and 
12*2 ±  5*7 AU for the six increasing adenosine 
dosages, respectively. In the controls, these values
were 57-5 ±7-6, 58*5 ±7*2, 56-1 ±7*7, 45*8 ±9*0, 
24*6±5*5, 16*0± 4*6 and 13*2± 5*2 AU respectively. 
Overall, the course of FVR in the infused arm did not 
significantly differ between the two groups (between- 
subject effect: P =  0*2). In both groups, FVR in the 
control arm was not affected. Similar results were
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Figure 2. Adenosine-induced forearm vasodilatation in controls (O) and diabetic patients ( • )  expressed as absolute (A) and 
percentage change (B) from baseline of the forearm vascular resistance (FVR). P values indicate the level of significance for 
betwccn-group effects (a n o v a  for repeated measurements). P  =  not significant.
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obtained when adenosine-induced changes in FVR 
were expressed as absolute or relative changes from
baseline (see Fig.2).
Because we observed slight differences in baseline 
FBF and FVR values between the diabetic 
patients and the control group, we also analysed 
the results of the FBF ratio (FBFjnfused arm divided 
by FBFconlraiaterai arm)- Assessment of the per cent 
changes in this ratio has been shown to be an appro­
priate method to analyse dose-response curves [22,42]. 
During placebo infusion, the FBF ratio was equal in 
both groups and had a value of numbered l-2 ±  0*1.
In the diabetic patients, the FBF ratios increased to 
1 *0 ±  0*1, 1*2 ±  0*1, 2*1 ±  0*4, 4*4 ±1*0, 5*9 ±  1*2 and 
9-2 ± 2*5 during the six increasing adenosine dosages 
respectively. In the controls, these values were
1*3±0*1, 1*5± 0-2, 2*2 ±0*4, 4*2 ±0-8, 8*9±1*5 and
14*7 ±  2*1 respectively. Overall, the course of the ratio 
did not significantly differ between the two groups 
(between-subject effect: P =  0*2). Similar results were 
obtained when adenosine-induced changes in the ratio 
were expressed as absolute or relative changes from 
baseline.
The minimal FVR that occurred during post-occlu­
sive reactive hyperaemia did not differ between dia­
betic patients and controls: 3*2±0*2 vs. 3*4±0*3 AU 
{P =  0*6). The individual courses of blood glucose 
concentration are shown in Fig.3. Within each indi­
vidual, glucose levels remained reasonably stable. 
However, between patients a high variation in aver­
aged glucose level existed ranging from 3*4 to 
20*6 mmol L. There was no correlation between the 
individual plasma glucose concentration and -the 
vascular responsiveness to adenosine in the diabetic 
patients (/* =  —0*2, P =  0*5). Plasma insulin concen­
tration was 21 *8 ±2-5 m equiv. L ” 1 (« =  9) in the 
diabetic patients versus 6*5 ±1*3 m equiv. L {n =  4) 
in the controls (P < 0*01). In four diabetic patients, 
insulin antibodies could be detected. After exclusion 
of these patients, plasma insulin concentration was 
still significantly higher in the diabetic patients as
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Figure 3. Individual courses of blood glucose concentrations, 
demonstrating the large inter-individual variability as well as the 
small intraindividual variability during the experiments.
compared with the control subjects (20*8 ±3*8 vs. 
6*5 ±  0*9 m equiv. L; P  <  0*05).
Discussion
This study was performed to investigate whether the 
forearm vasodilator response to adenosine is affected 
in patients with insulin-dependent diabetes mellitus. 
Normotensive non-smoking diabetic patients without 
evidence of macro- or microvascular complications 
were selected to prevent possible confounding 
by structural arteriolar or microvascular changes. 
Maximal forearm vasodilatation in the diabetic 
patients appeared to be equal to that of the age- 
matched control group, confirming the absence of 
structural abnormalities in the forearm vascular bed 
of the diabetic subjects. In these carefully selected 
patients, we observed a preserved vasodilator 
response to adenosine in the forearm vascular bed. 
This observation argues against a primary role for 
reduced adenosine responsiveness in the cardiovascu­
lar sequelae of diabetes.
The current results are in contrast with several 
observations in animal models for diabetes [9,10] 
that studied the responsiveness of the heart and 
coronary vasculature to adenosine. We cannot 
exclude the possibility that diabetes mellitus differen­
tially affects the coronary and forearm vascular bed in 
humans. However, other possible explanations should 
be discussed as well.
It has to be emphasized that animal models for 
diabetes represent a true insulinopenic state. In con­
trast, as a result o f subcutaneous administration of 
insulin as opposed to the physiological release of 
insulin into the portal vein, the levels of insulin are 
elevated in treated patients with insulin-dependent 
diabetes mellitus. As such, treated patients with insu­
lin-dependent diabetes do not represent an insulino­
penic state, not even in the fasting state when plasma 
insulin concentrations reach their trough level. This 
may well explain the preserved adenosine responsive­
ness in our patients, because treatment of diabetic 
animals with insulin also restored the impaired 
responses to adenosine [10]. Since we did not study 
the effects of adenosine in a true insulinopenic state, 
our data do not exclude an interaction between insulin 
and adenosine. Nonetheless, our present results do 
allow the conclusion that the vascular responsiveness 
to adenosine is preserved in patients with diabetes 
mellitus who are regularly treated with insulin.
In the diabetic patients, baseline forearm blood flow 
and forearm vascular resistance were slightly different 
from that of the control subjects. This interesting 
phenomenon has been described before [22] and is 
not only confined to the forearm but has also been 
shown for the retinal, renal and cutaneous circulation 
[43-45], It already exists in the early course of the 
disease before diabetic complications have developed 
[22,45]. Although the exact mechanism of this ‘hyper­
dynamic circulation’ in diabetic patients is not known,
©  1996 Blackwell Science Ltd, European Journal o f Clinical Investigation, 26, 192-198
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it may be related to the development of complications 
such as diabetic nephropathy and diabetic micro­
angiopathy [45]. Especially because of this difference 
in baseline forearm blood flow, we also included the 
results on the FBF ratio (see Methods). For the FBF- 
ratio, the diabetic patients and the control group had 
exactly the same baseline values. Using this para­
meter, statistical analysis of the adenosine responses 
revealed no difference between the two groups.
The main observation of the present study is that 
adenosine-mediated forearm vasodilatation is not 
significantly affected in insulin-dependent diabetic 
patients. The response to the two highest adenosine 
dosages tended to be slightly reduced in the diabetic 
patients, but this difference did not reach statistical 
significance. In contrast to the two highest dosages, 
the responses to the lower dosages were very similar 
between the two groups. We regard these lower 
dosages as being more representative for the local 
physiological increases in adenosine concentration, 
which are probably needed for the small adjustments 
of local flow in order to constantly balance tissue 
oxygen demand and supply.
The effect of intra-arterially supplied adenosine is 
determined by the adenosine concentration, adenosine 
receptor density and receptor function. Adenosine con­
centrations depend on the rate of cellular adenosine 
uptake. In theory, diabetes mellitus may impair this 
cellular uptake of adenosine [46]. Therefore, a reduced 
adenosine receptor density or function could have been 
masked by differences in adenosine kinetics between the 
two groups. However, the clinical significance of a 
possible receptor dysfunction is limited when the overall 
vasodilator effect of adenosine is not reduced in vivo as 
shown in the present study.
In conclusion, the vasodilator response to adeno­
sine is preserved in patients with insulin-dependent 
diabetes mellitus who are regularly treated with insu­
lin. This observation argues against a primary role of 
impaired adenosine responsiveness in the cardio­
vascular sequelae of diabetes.
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